MindBio Therapeutics Expands AI Intoxication Detection with New Software Platform

MindBio Therapeutics Corp., a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has expanded its artificial intelligence-based platform with the rollout of Intox Collect™. This new software tool is designed to broaden the company’s data collection and analytics capabilities across a wider range of substances that affect the central nervous system. The technology enhances the company’s ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment, moving detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants.

The company’s AI model currently uses more than 50 million data points, with management expecting that figure to increase further as the platform develops. This expansion of data collection through Intox Collect™ is critical for improving the accuracy and scope of impairment detection. The implications for workplace safety are significant, particularly in industries where intoxication poses severe risks. Target industries include mining, aviation, construction, law enforcement, and any environments where intoxication testing is frequently required for safety and compliance.

MindBio is also developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. This hardware integration represents the next phase in making this AI detection technology accessible and operational in real-world settings. The combination of advanced software like Intox Collect™ and dedicated hardware could standardize and streamline impairment screening in critical sectors. For investors and stakeholders following the company’s progress, the latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.

The launch of Intox Collect™ matters because it addresses a growing need for comprehensive, non-invasive impairment detection that goes beyond traditional breathalyzer tests. As workplaces face increasing scrutiny over safety protocols and duty-of-care responsibilities, technologies that can detect a broader spectrum of intoxicating substances become essential. This development positions MindBio at the forefront of applying AI and biometric data analytics to solve complex public health and safety challenges. The move from alcohol-only detection to a multi-substance platform reflects an understanding of modern substance use patterns and the corresponding risks in industrial and transportation environments.